Eli Lilly reported Phase II data showing its amylin receptor agonist eloralintide achieved dose‑dependent weight losses up to ~20% at Week 48 with an apparently favorable GI tolerability profile, prompting a planned move into Phase III. Results presented at ObesityWeek included multiple dose arms and signaled competitiveness with other amylin and GLP‑1 class programs. Lilly emphasized eloralintide’s tolerability with slower dose escalation reducing GI events; the company said it would start a registrational Phase III program soon. The data intensify the race for second‑generation obesity medicines — an area already shaped by Novo and Lilly GLP‑1 franchises and multiple amylin and dual agonist entrants. Investors and competitors will watch how comparative efficacy, safety, combination strategies and commercial pricing play out as the obesity market’s commercial dynamics evolve rapidly.